NICE recommends statins for patients with CKD
Healthcare professionals should offer statins to millions of people with chronic kidney disease (CKD) to help to manage their increased risk of cardiovascular disease (CVD), according to new guidance from NICE.
A new NICE standard www.nice.org.uk/guidance/qs5 lists atorvastatin as the preferred statin to offer patients because it is both clinically and cost effective. This is the third quality statement in the new standard which also includes statements on identification and monitoring of CKD and blood pressure control.
Professor Gillian Leng, deputy chief executive at NICE, said: “We know that a high number of people with long-term kidney problems will develop cardiovascular disease. This means they have an increased risk of suffering a fatal heart attack or stroke. It is important for healthcare professionals to speak to patients about their treatment options. The effectiveness of statins is now well proven, as is their long term safety. They may appeal to a lot of people who are at risk.”
The new Quality Statement 3 for 2017 says:
Research has shown there is a clear link between reduced kidney function and CVD. Around 2.6 million people in England have CKD and approximately 60,000 people die prematurely each year because of the disease.
NICE Quality Standard: Chronic kidney disease in adults (QS95) www.nice.org.uk/guidance/qs5